Free Trial

UCB (OTCMKTS:UCBJF) Hits New 12-Month High - Here's What Happened

UCB logo with Medical background

UCB SA (OTCMKTS:UCBJF - Get Free Report) shares hit a new 52-week high during trading on Wednesday . The stock traded as high as $195.88 and last traded at $195.88, with a volume of 87 shares traded. The stock had previously closed at $174.00.

UCB Price Performance

The company has a 50 day moving average of $179.62 and a 200 day moving average of $164.54. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33.

UCB Company Profile

(Get Free Report)

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

→ Did You See Trump’s Bombshell Exec. Order 001? (From Banyan Hill Publishing) (Ad)

Should you invest $1,000 in UCB right now?

Before you consider UCB, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UCB wasn't on the list.

While UCB currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Hershey’s Dividend Growth: A Sweet Pick for Investors

Hershey's isn't just a household name; it's a reliable pick for dividend growth, now up 15% this year and a 3-year average annualized 12.2% return.

Related Videos

Inflation-Busting Dividends: 3 Stocks Raising Payouts 4X Faster

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines